애들라이 노티(ANL)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $15.75 (+3.08%), 시가총액 $0.87B, 52주 최저~최고 $0.88 ~ $16.60.
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed
애들라이 노티의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
애들라이 노티의 현재 주가는 $15.75 (+3.08%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
애들라이 노티의 시가총액은 약 $0.87B입니다.
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 a